Please login to the form below

Novavax

This page shows the latest Novavax news and features for those working in and with pharma, biotech and healthcare.

American Medical Association calls for COVID-19 vaccine development transparency

Among the companies selected to receive funding as part of the initiative includes Johnson &Johnson, AstraZeneca/Oxford University, Pfizer/BioNTech, GlaxoSmithKline/Sanofi, Moderna and Novavax.

Latest news

Novavax CEO anticipates filing COVID-19 vaccine for approval in December

Pfizer also announces over 50% enrolment in COVID-19 vaccine trial. Novavax CEO Stanley Erck has said that the company is aiming to file its COVID-19 vaccine for approval by ... Novavax has already started enrolment for the phase 2 portion of its ongoing
Moderna’s COVID-19 vaccine shows promise in older adults

A number of other companies, including Johnson &Johnson, Pfizer, Novavax, AstraZeneca, GlaxoSmithKline and Sanofi, have signed similar deals with the US government.
COVID-19 vaccine deals with the EU hindered by strict liability rules

Meanwhile, the UK has reached deals with J&J, Novavax, GlaxoSmithKline, Sanofi and AstraZeneca/Oxford University, although the details of the liability rules within these agreements have not been disclosed.
Novavax begins phase 2 portion of COVID-19 vaccine trial

Novavax has initiated a phase 2 trial of its COVID-19 vaccine candidate, NVX-CoV2373, in the US and Australia. ... responses in older adults,” said Gregory Glenn, president, research and development at Novavax.
US payments for COVID-19 vaccines tied to specific timing milestones

This includes candidates from Johnson &Johnson, Pfizer/BioNTech, Sanofi/GlaxoSmithKline, AstraZeneca/Oxford University and Novavax.

More from news
Approximately 6 fully matching, plus 18 partially matching documents found.

Latest Intelligence

Developing a COVID-19 vaccine

The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
Deal Watch table for June 2013

30. Isconova / Novavax. Acquisition. Proprietary vaccine adjuvant technology. 30. Unless noted, transactions are for global rights.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Dutch biotech Mucosis promotes Thomas Johnston to CEO

Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...